Recent Updates
Recently added Catalysts

NXL Energy 1

Phase 1

Progressive Keratoconus | Small molecule | Ophthalmology |Glaukos Corporation|Last Updated: Jul 8, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment150
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05314738Safety and Efficacy of Corneal Cross-linking in Subjects With KeratoconusPHASE1 RECRUITING 150Mar 8, 2022Feb 1, 2026Jul 8, 20243 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Topography
12 Months

Change in Kmax topography value from baseline

Secondary Endpoints
Distance Uncorrected Visual Acuity (UCVA)
12 Months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Riboflavin Ophthalmic Solution and UV-A Irradiation Group 1 / Cohort 1EXPERIMENTALRiboflavin Solution + Exposure to NXL system to achieve total energy level 3
Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 / Cohort 2AACTIVE_COMPARATORRiboflavin Solution + Exposure to NXL system to achieve total energy level 1
Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 / Cohort 2AACTIVE_COMPARATORRiboflavin Solution + Exposure to NXL system to achieve total energy level 2
Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 / Cohort 2AACTIVE_COMPARATORRiboflavin Solution + Exposure to NXL system to achieve total energy level 3
Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 / Cohort 2BACTIVE_COMPARATORRiboflavin Solution + Exposure to NXL system to achieve total energy level 1
Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 / Cohort 2BACTIVE_COMPARATORRiboflavin Solution + Exposure to NXL system to achieve total energy level 2
Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 / Cohort 2BACTIVE_COMPARATORRiboflavin Solution + Exposure to NXL system to achieve total energy level 3
Placebo Group 2 / Cohort 2BSHAM_COMPARATORSham Solution with no exposure to NXL System
Interventions
NameTypeDescription
NXL Energy 1COMBINATION_PRODUCTRiboflavin drops + NXL System to Total Energy Level 1
NXL Energy 2COMBINATION_PRODUCTRiboflavin drops + NXL System to Total Energy Level 2
NXL Energy 3COMBINATION_PRODUCTRiboflavin drops + NXL System to Total Energy Level 3
Sham TreatmentCOMBINATION_PRODUCTSham Drops and No exposure to NXL system
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Provide written informed consent * Ability to hold gaze sufficiently stable for study testing * Willingness and ability to follow all instructions and comply with schedule for follow-up visits * Have a diagnosis of keratoconus Exclusion Criteria: * Known allergy or sensitivi...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT05314738primaryCompletionDate: changed
LOWMay 24, 2026NCT05314738studyFirstPostDate: changed